Prognostic value of sarcopenia in survivors of hematological malignances undergoing a hematopoietic stem cell transplantation: a systematic review and meta-analysis

[1] Ljungman P(2010)Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009 Bone Marrow Transplant 45 219-234

[2] Bregni M(2016)Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually Bone Marrow Transplant 51 786-792

[3] Brune M(2008)What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol 21 667-675

[4] Cornelissen J(2009)Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15 367-369

[5] de Witte T(2011)Long-term survival and late deaths after allogeneic hematopoietic cell transplantation J Clin Oncol 29 2230-2239

[6] Dini G(2014)A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20 937-945

[7] Einsele H(2019)Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors Bone Marrow Transplant 55 126-136

[8] Gaspar HB(2017)Costs of hematopoietic stem cell transplantation in a developing country Int J Hematol 106 573-580

[9] Gratwohl A(2018)Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes Expert Rev Hematol 11 805-816

[10] Passweg J(2018)International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management The journal of nutrition, health & aging 22 1148-1161

[1] Ljungman P(2010)Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe 2009 Bone Marrow Transplant 45 219-234

[2] Bregni M(2016)Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually Bone Marrow Transplant 51 786-792

[3] Brune M(2008)What is the impact of hematopoietic cell transplantation (HCT) for older adults with acute myeloid leukemia (AML)? Best Pract Res Clin Haematol 21 667-675

[4] Cornelissen J(2009)Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 15 367-369

[5] de Witte T(2011)Long-term survival and late deaths after allogeneic hematopoietic cell transplantation J Clin Oncol 29 2230-2239

[6] Dini G(2014)A population-based cohort study of late mortality in adult autologous hematopoietic stem cell transplant recipients in Australia Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation. 20 937-945

[7] Einsele H(2019)Death after hematopoietic stem cell transplantation: changes over calendar year time, infections and associated factors Bone Marrow Transplant 55 126-136

[8] Gaspar HB(2017)Costs of hematopoietic stem cell transplantation in a developing country Int J Hematol 106 573-580

[9] Gratwohl A(2018)Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes Expert Rev Hematol 11 805-816

[10] Passweg J(2018)International Clinical Practice Guidelines for Sarcopenia (ICFSR): screening, diagnosis and management The journal of nutrition, health & aging 22 1148-1161